# P. Sherrill Neff

> P. Sherrill Neff is a Series C investor at Quaker Partners backing Health Care and Therapeutics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Quaker Partners](https://shizune.co/investors/profile/quaker-partners)
- Location: Merion Station, United States
- Total investments: 3
- Last investment: Aug 2010
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/sherrill-neff-9185b3
- X (Twitter): http://twitter.com/SherrillNeff

P. Sherrill Neff is a Series C investor at Quaker Partners in Merion Station focused on Health Care and Therapeutics. Founding Partner of Quaker PartnersPreviously: President, COO, and Director, Neose Technologies, a publicly traded life sciences company. Senior VP, Corporate Development, U.S. Healthcare, a leading publicly traded HMO. Managing Director, Investment Banking Division, Alex. Brown & Sons. Corporate Attorney at Morgan, Lewis & Bockius.Board Responsibilities: Cempra Pharmaceuticals, Intact Vascular, Neuronetics, RainDance Technologies, and Regado BiosciencesOther Investment Responsibilities: Achillion Pharmaceuticals, Durata Therapeutics and Horizon PharmaPrior Board Participation: Amicus Therapeutics, Biolex, BioRexis (acquired by Pfizer) and Medmark (acquired by Walgreen Co.), and Optherion.Other: Board of Directors, National Venture Capital Association (NVCA); Board of Directors, Resource Capital Corporation (NYSE:RSO); Chairman, Policy Board, WXPN-FM, listener supported radio from the University of Pennsylvania. Former Chairman, Greater Philadelphia Venture Group; Former President, Pennsylvania Biotechnology Association. Former board member, University City Science Center, Biotechnology Institute, and Vesper Boat Club. Former board member of the following publicly traded companies: Neose Technologies, Jefferson Bank, The Bancorp, and Resource America.Education: B.A. from Wesleyan University and J.D. magna cum laude from the University of Michigan Law School

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 33% |
| Series D | 1 | 33% |
| Post-IPO Equity | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Achillion Pharmaceuticals | At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Ourprincipal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system. | $50.1M | Post-IPO Equity | Aug 18, 2010 |  |
| Regado Biosciences | Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $40M | Series D | Dec 17, 2009 |  |
| Regado Biosciences | Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $23M | Series C | Mar 27, 2007 |  |

3 of 3 investments shown.

## Co-investors
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [The Aurora Funds](https://shizune.co/investors/profile/the-aurora-funds) — VC Fund, 2 deals together
- [Clarus Ventures](https://shizune.co/investors/profile/clarus-ventures) — VC Fund, 1 deal together
- [Pappas Ventures](https://shizune.co/investors/profile/pappas-ventures) — VC Fund, 1 deal together

## About Quaker Partners

VC Fund · Philadelphia, United States

Quaker Partners is a healthcare investment firm focused on companies based on the U.S. East Coast.

2 contacts available at Quaker Partners.

| Name | Title | Profile |
| --- | --- | --- |
| P. Sherrill Neff | Partner | https://shizune.co/investors/profile/p-sherrill-neff |
| Brian Schwenk | CFO | https://shizune.co/investors/profile/brian-schwenk |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does P. Sherrill Neff invest in?

P. Sherrill Neff invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series C and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did P. Sherrill Neff last invest?

The most recent investment recorded for P. Sherrill Neff closed in Aug 2010. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co